HCW Biologics appoints Gary Winer and Lisa Giles to board of directors

HCW Biologics Inc.

HCW Biologics appointed Gary Winer as Class I director and Lisa Giles as Class II director, effective Oct 25, 2021.
Both new directors appointed to audit and compensation committees; Dr. Hing Wong stepped down from audit committee.
Winer was CEO of ORGENTEC Diagnostika until Sept 2021; Giles is founder/CEO of Giles & Associates Consultancy.
Directors compensated per Non-Employee Director Compensation Policy, pro-rated; indemnification agreements to be signed.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Lisa Giles

Director

HCWB · HCW Biologics Inc.

Effective: 2021-10-25
Filed: October 27, 2021, 7:59 PM ET

appointed Gary Winer as a Class I member of the Board and Lisa Giles as a Class II member of the Board, in each case effective October 25, 2021.

Appointed

Gary Winer

Director

HCWB · HCW Biologics Inc.

Effective: 2021-10-25
Filed: October 27, 2021, 7:59 PM ET

appointed Gary Winer as a Class I member of the Board and Lisa Giles as a Class II member of the Board, in each case effective October 25, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Lisa Giles was appointed as Director at HCW Biologics Inc..

Action: appointed
Role: Director

Exact text from the filing

appointed Gary Winer as a Class I member of the Board and Lisa Giles as a Class II member of the Board, in each case effective October 25, 2021.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Gary Winer was appointed as Director at HCW Biologics Inc..

Action: appointed
Role: Director

Exact text from the filing

appointed Gary Winer as a Class I member of the Board and Lisa Giles as a Class II member of the Board, in each case effective October 25, 2021.

View on SEC.gov

HCW Biologics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-308673

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.